ストックスクリーナーアプリを入手
19.94
0.86%
0.17
プレマーケット:
20.11
0.17
+0.85%
前日終値:
$19.77
開ける：
$19.78
24時間の取引高:
1.11M
Relative Volume:
0.72
時価総額：
$1.77B
収益：
$217.42M
当期純損益:
$-243.25M
株価収益率:
-7.1337
EPS:
-2.7952
ネットキャッシュフロー:
$-278.35M
1週間 パフォーマンス:
-1.43%
1か月 パフォーマンス:
-9.69%
6か月 パフォーマンス:
+14.33%
1年 パフォーマンス:
+84.46%
1日の値動き範囲:
$19.75
$20.55
1週間の範囲:
$19.00
$20.83
52週間の値動き範囲:
$8.585
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
名前
Syndax Pharmaceuticals Inc
セクター
電話
781-419-1400
住所
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
19.94 | 1.75B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-16 | 再開されました | H.C. Wainwright | Buy |
| 2025-09-10 | 再開されました | Stifel | Buy |
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-08-05 | 繰り返されました | BTIG Research | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-06-28 | 開始されました | Jefferies | Buy |
| 2024-01-31 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 開始されました | Mizuho | Buy |
| 2023-10-25 | 開始されました | BofA Securities | Buy |
| 2023-10-11 | 開始されました | Goldman | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-11 | 開始されました | Guggenheim | Buy |
| 2023-04-17 | 再開されました | BTIG Research | Buy |
| 2023-01-31 | 開始されました | Stifel | Buy |
| 2023-01-03 | 開始されました | JP Morgan | Overweight |
| 2022-07-28 | 再開されました | B. Riley Securities | Buy |
| 2022-04-11 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-15 | 開始されました | Goldman | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-25 | 開始されました | Citigroup | Buy |
| 2021-02-18 | 開始されました | B. Riley Securities | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-05-22 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-05-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-01-04 | 開始されました | Robert W. Baird | Outperform |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 開始されました | FBR & Co. | Outperform |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2016-10-07 | 開始されました | Guggenheim | Buy |
| 2016-03-28 | 開始されました | Citigroup | Buy |
| 2016-03-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-03-28 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness - Yahoo Finance
SNDX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Assessing Syndax Pharmaceuticals (SNDX) Valuation After New Revuforj Leukemia Data Spurs Investor Interest - Sahm
Syndax Pharmaceuticals to Present Key Revumenib Data at ASCO 2026, Highlighting Post-Transplant Outcomes and Pharmacokinetic Insights - Quiver Quantitative
Leukemia drug revumenib data to headline 4 ASCO 2026 talks - Stock Titan
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Syndax Pharmaceuticals’ SWOT analysis: stock gains momentum on strong launch - Investing.com UK
Syndax Announces Participation in Upcoming Investor Conferences - 富途牛牛
Which Is a Better Investment, Syndax Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. Stock? - AAII
Point72 (SNDX) reports 1,985,547 shares, 2.3% stake in Syndax - Stock Titan
(SNDX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Does Expanded Revuforj Leukemia Data Set Change The Bull Case For Syndax Pharmaceuticals (SNDX)? - Sahm
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential - Insider Monkey
UBS Trims Price Target on Syndax Pharmaceuticals to $37 From $38, Maintains Buy Rating - Moomoo
UBS Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
SNDX Maintained by UBS -- Price Target Lowered to $37.00 - GuruFocus
Syndax (SNDX) Highlights Revuforj Data Ahead of EHA Congress - GuruFocus
Syndax Pharmaceuticals stock (US88906L1052): Analyst upgrade drives 6.6% gain - AD HOC NEWS
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition - The Manila Times
Syndax Highlights 12 Revuforj® (revumenib) Abstracts - GlobeNewswire
Leukemia drug revumenib lands 12 studies at European Hematology meeting - Stock Titan
TradingKey - TradingKey
Assessing Syndax Pharmaceuticals (SNDX) Valuation After Stronger Revenue And Narrower Losses - simplywall.st
SNDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Syndax Pharmaceuticals (SNDX): Analyst Ratings Suggest A 92% Upside Potential - DirectorsTalk Interviews
SNDX Stock Price, Quote & Chart | SYNDAX PHARMACEUTICALS INC (NASDAQ:SNDX) - ChartMill
SNDX SEC FilingsSyndax Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Eight new Syndax hires get stock options for 162,100 shares - Stock Titan
MSN Money - MSN
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $46 - Moomoo
Syndax Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-05-05 - Seeking Alpha
HC Wainwright Has Optimistic Outlook of SNDX Q2 Earnings - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
(SNDX) Risk Channels and Responsive Allocation - Stock Traders Daily
Biotech Momentum Builds As Syndax Pharmaceuticals Draws Market Attention - Kalkine Media
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Released Its First-Quarter Earnings: Here's What Analysts Think - 富途牛牛
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade - MarketBeat
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook By Investing.com - Investing.com Canada
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook - Investing.com
HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings - MarketBeat
Syndax Pharmaceuticals (SNDX) Is Down 10.7% After Revenue Surges And Loss Narrows In Q1 2026 - simplywall.st
Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives - Sahm
Net current asset value per share of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Syndax Pharmaceuticals Q1 Loss Narrows, Revenue Rises - Moomoo
Syndax Pharmaceuticals Reports Over $100 Million in Q1 Combined Sales - HarianBasis.co
Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
Syndax Pharmaceuticals 1Q Loss $42.7M >SNDX - Moomoo
Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain TractionWhat’s Really Shifting? - Yahoo Finance UK
Syndax Pharmaceuticals Inc (SNDX) 財務データ
収益
当期純利益
現金流量
EPS
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):